Innovating to end HIV

An increasingly robust portfolio
Unitaid’s investments in HIV and related illnesses have more than doubled in 4 years, and they make up nearly half of our US$ 1.3 billion grant portfolio.

Our game-changing investments include

**Prevention**
Preventive medicines (PrEP) for people at high risk

$37 m

**Testing**
HIV self-testing to increase the number of people living with HIV that are aware of their status and improved infant diagnosis

$213.3 m

**HIV-related illnesses**
Better tools to screen, prevent and treat coinfections and comorbidities in people living with HIV (advanced HIV disease, cervical cancer, hepatitis C)

$126.5 m

**Treatment and monitoring**
Antiretroviral treatments that are cheaper, safer and less prone to drug resistance as well as formulations adapted for children. Viral load tests to monitor if the treatments are working

$99.2 m

Unitaid’s current main funders are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation. Unitaid is a hosted partnership of the World Health Organization.